论文部分内容阅读
我院神经内科于2000年2月至2001年2月间观察了盐酸纳洛酮注射液(商品名苏诺,由北京四环制药公司生产)治疗急性脑梗死的疗效,并同期与低分子葡聚糖治疗组作对照研究。现将研究结果报道如下。1 临床资料1.1 病例选择全部入选病例均符合 1995年全国第四届脑血管病学术会议通过的脑梗死诊断要点。入选标准:(1)发病10天内的首次发病或过去发病未留下神经功能缺损的急性脑梗死病人;(2)病因考虑为高血压动脉硬化性者;(3)有确切的持续的神经系统定位特征:(4)头颅CT检查确诊,除外脑出血;(5)血压<160/100mmHg,排除心、肺、肝、肾功能衰竭及中重度昏迷者。
Neurology in our hospital from February 2000 to February 2001 were observed naloxone hydrochloride injection (trade name Su Nuobu, Beijing Sihuan Pharmaceutical Company) for the treatment of acute cerebral infarction, and the same period and low molecular weight of Portuguese Glycan treatment group as a control study. The research results are reported below. 1 Clinical data 1.1 Case Selection All selected cases are in line with the 1995 Fourth National Cerebrovascular Disease Conference approved the diagnosis of cerebral infarction points. Inclusion criteria: (1) patients with acute cerebral infarction who did not have neurological deficits for the first time within 10 days of onset of disease, (2) those who were at risk for arteriosclerosis, and (3) those who had a definite and sustained nervous system Positioning characteristics: (4) head CT examination confirmed, except for intracerebral hemorrhage; (5) blood pressure <160 / 100mmHg, exclude heart, lung, liver and kidney failure and moderate to severe coma.